Wells Fargo & Company MN Has $674,000 Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Wells Fargo & Company MN trimmed its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 61.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 70,047 shares of the company’s stock after selling 110,595 shares during the period. Wells Fargo & Company MN’s holdings in MiMedx Group were worth $674,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of MDXG. IMG Wealth Management Inc. acquired a new stake in shares of MiMedx Group during the 4th quarter worth approximately $28,000. Van ECK Associates Corp bought a new position in shares of MiMedx Group in the 4th quarter valued at $40,000. SkyView Investment Advisors LLC lifted its position in shares of MiMedx Group by 30.0% during the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company’s stock worth $77,000 after buying an additional 3,000 shares during the last quarter. AlphaQuest LLC acquired a new position in MiMedx Group during the fourth quarter worth about $88,000. Finally, Savant Capital LLC bought a new position in shares of MiMedx Group in the fourth quarter worth about $100,000. 79.15% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 price objective on shares of MiMedx Group in a research report on Thursday, February 27th. StockNews.com upgraded shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Thursday.

MiMedx Group Stock Performance

NASDAQ:MDXG opened at $6.32 on Friday. The stock’s 50-day moving average is $7.44 and its 200-day moving average is $8.07. The stock has a market cap of $931.35 million, a P/E ratio of 11.49 and a beta of 1.74. MiMedx Group, Inc. has a 1-year low of $5.47 and a 1-year high of $10.14. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.06. The firm had revenue of $88.21 million for the quarter, compared to analyst estimates of $86.32 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. Equities research analysts anticipate that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Insider Activity at MiMedx Group

In other MiMedx Group news, CAO William Frank Iv Hulse sold 81,446 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $7.80, for a total transaction of $635,278.80. Following the completion of the transaction, the chief accounting officer now owns 494,774 shares in the company, valued at approximately $3,859,237.20. This trade represents a 14.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the company’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $32,396.34. Following the completion of the sale, the insider now directly owns 310,836 shares in the company, valued at approximately $2,452,496.04. This represents a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 144,018 shares of company stock worth $1,130,312 over the last three months. Company insiders own 1.30% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.